Nkarta Inc

-0.58 (-6.69%)
7:30:55 PM EDT: $8.17 +0.08 (+0.99%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Nkarta Inc Stock, NASDAQ:NKTX

6000 Shoreline Court, Suite 102, South San Francisco, California 94080
United States of America
Phone: +1.415.582.4923
Number of Employees: 136


Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firmâ??s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.